Robert A. Hutchinson

Ravenscroft (CI) Ltd. provides management consultancy services other than financial management. The company was founded by Jonathan Richard Ravenscroft and Andrew Marshall Stewart on March 8, 2005 and is headquartered in St. Peter Port, the United Kingdom.

Ravenscroft Ltd. (Private Equity) is an independent private equity subsidiary of Ravenscroft Ltd. founded in 2005. The firm is headquartered in St. Peter Port.

Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.

Syncona Investment Management Ltd. (Syncona) is the asset management subsidiary of Syncona Ltd. in Great Britain. Headquartered in London, the firm was co-founded by Martin Murphy alongside The Wellcome Trust. Syncona is focused on founding, building and funding a portfolio of global leaders in life science.

Part of abrdn Plc, Standard Life Investments (Holdings) Ltd. is a British company that provides asset management services. The company is based in Lothian, UK.

Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.

Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA.

Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom.

Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

Columbia Threadneedle Asset Managers Ltd. (CTAM) is an asset management firm headquartered in London, UK. The firm was founded in 1990 as F&C Asset Managers Ltd. and renamed BMO Asset Managers Ltd. in 2018. They changed their name to Columbia Threadneedle Asset Managers Ltd. when BMO rebranded to Columbia Threadneedle Investments in 2022. The firm is a subsidiary of Columbia Threadneedle AM (Holdings) Plc, ultimately held by Ameriprise Financial, Inc. (NYSE: AMP) in the US. CTAM manages a range of in-house and multi-manager funds for private individuals and institutional clients.

Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands.

DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France.

VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.

Salvia BioElectronics BV develops a bioelectronics therapy for people suffering from chronic neurological diseases. The company was founded by Sjaak Deckers and Hubert Martens in 2017 and is headquartered in Eindhoven, the Netherlands.

NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.

Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.

QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA.

Aveni SA designs, develops, manufactures and markets chemical formulations. It enables future technologies with its approach to metallization for semiconductor, MEMS, advanced packaging, and flex applications. The company was founded in 2001 and is headquartered in Massy, France.

INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam.

Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA.

iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland.

ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland.

Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA.

Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA.

Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark.

T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018.

Part of Teneo Holdings LLC, Ridgeway Partners Holdings Ltd. is a 25-person executive search firm with offices in multiple locations. The company is based in London, UK. Ridgeway Partners differentiates itself with its creativity, tenacity, responsiveness, and unparalleled track record of success. The British company has built long-standing relationships with its clients because of its exclusivity, responsiveness, discretion, and track record of success. Founded in 2016, the company specializes in executive search, board appointments, and succession planning for a select group of multi-sector, domestic and international companies. Ridgeway Partners was acquired by Teneo Holdings LLC on January 04, 2021.